Pozen hires EMD exec as general counsel
bizjournals.com
Pozen hires EMD exec as general counsel
Wednesday January 10, 2:40 pm ET
Chapel Hill pharmaceutical firm Pozen Inc. said Wednesday it has appointed Gilda M. Thomas to the newly created position of senior vice president and general counsel.
Thomas, formerly vice president and general counsel for EMD Pharmaceuticals, a Durham-based affiliate of German drug giant Merck KGaA, will be responsible for all legal matters at Pozen.
Thomas will report directly to Pozen CEO John Plachetka, according to Pozen Investor Relations Director Fran Barsky.
Prior to joining EMD, Thomas worked for 14 years at the Research Triangle Park-based Burroughs Wellcome Co., which subsequently merged into what is today GlaxoSmithKline.
Pozen announced in December that federal regulators had raised questions about its lead migraine treatment, Trexima. Pozen is developing the drug with GSK.
The FDA had already requested additional information on the drug but deemed the company's response incomplete.
Pozen officials said the additional information will help the FDA assess the "relative safety of Trexima. The company has yet to provide any updated information on Trexima.
Pozen (Nasdaq: POZN - News) halted development of MT 100, another migraine drug, in August following an FDA committee's recommendation against approval because of safety concerns.
Published January 10, 2007 by the Triangle Business Journal
Pozen hires EMD exec as general counsel
Wednesday January 10, 2:40 pm ET
Chapel Hill pharmaceutical firm Pozen Inc. said Wednesday it has appointed Gilda M. Thomas to the newly created position of senior vice president and general counsel.
Thomas, formerly vice president and general counsel for EMD Pharmaceuticals, a Durham-based affiliate of German drug giant Merck KGaA, will be responsible for all legal matters at Pozen.
Thomas will report directly to Pozen CEO John Plachetka, according to Pozen Investor Relations Director Fran Barsky.
Prior to joining EMD, Thomas worked for 14 years at the Research Triangle Park-based Burroughs Wellcome Co., which subsequently merged into what is today GlaxoSmithKline.
Pozen announced in December that federal regulators had raised questions about its lead migraine treatment, Trexima. Pozen is developing the drug with GSK.
The FDA had already requested additional information on the drug but deemed the company's response incomplete.
Pozen officials said the additional information will help the FDA assess the "relative safety of Trexima. The company has yet to provide any updated information on Trexima.
Pozen (Nasdaq: POZN - News) halted development of MT 100, another migraine drug, in August following an FDA committee's recommendation against approval because of safety concerns.
Published January 10, 2007 by the Triangle Business Journal
posted by B at 7:52 PM
0 Comments:
Post a Comment
<< Home